WO1989009049A1 - Preparations pharmaceutiques homeopathiques magnetiquement influencees, leurs procedes de preparation et d'administration - Google Patents

Preparations pharmaceutiques homeopathiques magnetiquement influencees, leurs procedes de preparation et d'administration Download PDF

Info

Publication number
WO1989009049A1
WO1989009049A1 PCT/US1989/001400 US8901400W WO8909049A1 WO 1989009049 A1 WO1989009049 A1 WO 1989009049A1 US 8901400 W US8901400 W US 8901400W WO 8909049 A1 WO8909049 A1 WO 8909049A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
injectable
per day
magnetized
times per
Prior art date
Application number
PCT/US1989/001400
Other languages
English (en)
Inventor
Walter Whitson Fischman
Original Assignee
Walter Whitson Fischman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter Whitson Fischman filed Critical Walter Whitson Fischman
Priority to IN258/CAL/89A priority Critical patent/IN169075B/en
Publication of WO1989009049A1 publication Critical patent/WO1989009049A1/fr
Priority to IN1043/CAL/90A priority patent/IN171749B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention relates to homeopathic medicament? and methods for the treatment of illness and injury in human being ⁇ u ⁇ ir ⁇ such homeopathic medicaments.
  • the invention relates to homeopathic methods of treatment of conditions including illnesses, pathogenic diseases, allergies, chemical and hormonal imbalances, addictive chemical dependencies, and physical injuries to the human body.
  • the methods of treatment include oral, topical, auricular and injectable forms of homeopathic formulations which are magnetically treated or influenced during administeration to a patient through specific acupuncture points.
  • Homeopathy is an ancient healing art and forms a vital part of medical therapy.
  • the practice of homeopathy is widespread, particularly in eastern cultures and many European countries.
  • Homeopathic medicine teaches the use cf natural based remedies and, as such, provides an alternative to traditional allopathic medicine which relies heavily on the use of petrochemical based pharmaceuticals.
  • Homeopathic remedies use pharmaceutical preparations based on the use of herbs or herbal extracts.
  • Homeoparhic remedies function in a totally different manner than chemical-based pharmaceuticals in that _ ⁇ _ they do not require administering high concentration? of active ingredient to produce the desired results.
  • Traditional allopathic pharmaceuticals can be thought of as working quantitatively, that is, the results achieved are generally proportional to the potency and frequency of the dosage administered.
  • homeopathic pharmaceuticals can be thought of as working- qualitatively in that even the minutest quantities of their active ingredients produce a therapeutic effect by inducing natural body mechanisms to return to their proper level of activity characteristic of a healthful or uninjured state.
  • Homeopathic remedies function by inducing natural body mechanisms and processes to return to their optimum healthful level of operation; that is, their natural biological "set points". Through our modern understanding of genetics each bodily member and process is seen as the result of codes programmed into each individual cell.
  • Homeopathic medicine seeks to utilize natural substances, particularly herbs, to naturally and gently induce the body to restore its equilibri- um, that is, for all function and processes to return to their set points.
  • Homeopathic medicine looks upon illness and disease as being a state of disequilibrium from the body's optional set points.
  • a fundamental precept of homeopathic medicine is that a small force or stimulating agent can produce disproportionally greater results, if optimally and effectively applied.
  • homeopathic medicaments are relatively inexpensive as compared to traditional chemical-based pharmaceuticals.
  • Another fundamental precept in the formulation of homeopathic pharmaceuticals is that repetitive dilution from an original concentrate does not diminish efficacy of the formulation.
  • Acupuncture involves the relief of symptoms and the cure of illness and injury by the controlled stimulation of points on the human body which regulate or interact with the functioning of specific organs or bodily members to which the acupuncture points are related.
  • the pain cycle can be broken and the natural healing process induced.
  • Stimulation through acupunc- ture which typically involves the insertion of small needles into the acupuncture points on the body, causes a release of endorphins which block pain sensed over the neurological pathways and enable other natural healing mechanisms in the body to restore a condition of homeopathic equilibrium to the body by killing invasive pathogens, restoring chemical or hormonal imbalance . or fostering the mending of physically injured tissues, muscles and/or bones.
  • specific points on the human body have been determined which regulate the functioning of all bodily members and processes.
  • the appropriate points for stimulation for any given condition are known to skilled practitioners in the art.
  • One particular acupuncture treatment system developed in Japan by Dr. Yo ⁇ hic Manaka is based on a conception of the human body as encompassing two basic systems, an energetic system and an informational system.
  • the energetic system utilizes the greater portion of energy in the body.
  • the informational system controls the energetic system and responds to both external and internal stimuli.
  • Acupuncture is viewed, as a therapeutic modality which interacts with and regulates the body's informational system.
  • the human body's susceptibility to magnetic fields is due in large part to the electrolytic properties of many of the chemical constituents of the body. All electrolytic substances are capable of conducting an electric current and wherever an electric current is flowing, a magnetic field is created. The greater the electrolytic properties of the substance, the greater is its conductivity and therefore the greater the resulting magnetic field created during current flow.
  • the body generates a magnetic field of its own due " partly to the presence of iron ⁇ carrying charged particles flowing in the blood stream.
  • Other electrolytic substances in the body such as potassium and sodium, in ionic form, are present in substantial amounts and contribute to the body's overall bioelectric/biomagnetic field.
  • blood cells are readily polarized when placed in a magnetic field due to the high iron concentration in the blood. Under certain conditions, magnetic fields alter the orientation of blood cells and induce changes in the biological reactions in which they participate, thereby modifying the probability of chemical bond formation.
  • Human blood is very slightly alkaline with respect to body cells which are more acidic. Magnetic fields can be used to induce reactions which restore the pH of the blood.
  • Therapeutic magnetic energy fields also produce a stimulating component which in the case of traumatic physical injury dilates blood vessels and increases blood circulation, disperses fluid build-up due to inflammation, and strengthens and promotes the healing of damaged tissue.
  • pulsed magnetic energy has been observed to cause transcutaneous electrical neural stimulation and contributes to the reduction of chronic pain by causing the release of natural pain relieving substances at the spinal cord level and by causing the release of endorphins and ACTH at the pituitary gland level.
  • a primary object of the present in ⁇ vention is to disclose a new modality of medical therapy which utilizes aspects of homeopathic pharmaceutical therapy, acupuncture therapy and biomagnetic therapy, in combination.
  • a further object of the invention is to devise a full range of modes of administration of magnetically induced homeopathic remedies, including topical, injectable, auricular and oral forms.
  • a further object of the invention is to provide particular homeopathic pharmaceutical formulations for the treatment of specific illnesses, physical injuries and other chemical and hormonal disequilibrium conditions of the human body with precisely determined acupuncture sites to which the homeopathic pharmaceutical remedies are to be applied in the treatment of each specific condition.
  • a further object of the invention is to provide appropriate means for inducing the biomagnetic field in the homeopathic pharmaceutical remedy for each form of adminis ⁇ tration.
  • the present invention is directed to a method of treatment of human illness and injury by administering to the patient homeopathic medicaments through selected acupuncture points stimulated by a controlled magnetic field.
  • a very " broad spectrum of human illnesses can be effectively treated by homeopathic medicaments of the instant invention through selection of the appropriate homeopathic remedy, preparation of a mixture of the homeopathic remedy and a magnetically permeable component and magnetization of the resulting mixture, during administration to the patient through specific acupuncture sites.
  • Various embodiments of the invention include administering therapeutic amounts of the magnetic mixture in oral, injectable, topical and auricular forms. Further, depending upon the condition being treated the dosage and frequency of administration will vary. In a particularly preferred embodiment the patient is administered with a regimen of both oral and injectable dosages.
  • Figures 1A and IE show two preferred embodiments of oral delivery vehicles for the administration of homeopathic medicaments
  • Figures 2A and 2B show embodiments for the topical administration of a homeopathic medicament
  • Figure 3 shows a preferred embodiment for imparting a magnetic field to the injectable form homeopathic medicaments
  • the homeopathic medicaments of the present invention when administered through specific acupuncture sites have demonstrated remarkable efficacy in the treatment of a wide range of afflictions, many of which have no known cure in the realm of allopathic medicine.
  • Effective delivery systems for these homeopathic formulations have been devised including topical, injectable, auricular and oral forms.
  • the homeopathic medicament administered in whatever form is selected, must first be carefully mixed with an. effective amount of a magnetically permeable ingredient.
  • a magnetically permeable ingredient such as sodium sulfate, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium sulfate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium
  • One delivery system used is by injection.
  • the formulation dosage and duration of treatment for the injectible medicaments is described in detail in the formulation examples which follow. Since it has been observed that injecting homeopathic medicaments demonstrate unexpected and significantly enhanced efficacy when a unipolar magnetic charge is imparted to the medicament during administration or injection into an acupuncture point, a device has been developed to enable the administering physician to suitably charge the medicament.
  • One such device is shown in Figure 3. This device consists of a housing 10 containing an electromagnetic coil 12 positioned to impart a controlled magnetic charge to plate 14.
  • a syringe or hypodermic needle 16 used to inject the homeopathic medicament can be positioned in housing 10 such that the point of the needle or syringe is in close proximity to plate 14 as shown in Figure 3.
  • Topical Another alternative delivery system used is the topical.
  • the topical patch 20 is made cf a porous material such a ⁇ sintered metal capable of absorbing a therapeutic amount of homeopathic medicament.
  • the patch 20 has an extended opening therethrough in which is tightly fitted a metal rod or core 22 which can readily accept and retain a magnetic charge. Suitable materials include iron and nickel.
  • the patch 20 can then be impregnated with a therapeutic amount of desired homeopathic medicament.
  • a unipolar magnetic charge is then imparted to the metallic core 22 of patch 20 which is then affixed to a suitable acupuncture point.
  • One method for affixing the topical patch to the acupuncture point is to hold it in place with adhesive bandage, surgical tape or the like.
  • the magnetically influenced homeopathic medicament can be placed in a band which can be comfortably strapped around the member at the desired location.
  • the homeopathic pharmaceutical formulation can be magnetized _in situ by placing a permanent magnet or ether source of magnetic flux on top of the portion of the homeopathic mixture to be agnet- ically activated.
  • FIG. 2B Still another form of a topical for administering homeopathic medicaments is a pellet or "button" as illustrated in Figure 2B.
  • the button 30 can be stamped out under pressure in a process generally known as the sintered metal process.
  • a 50/50 powdered mixture of Ni (nickel) and Fe (iron) is fed into a press mold. This composition inhibits corrosion and readily accepts and holds a magnetic charge. Since the finished pellet or button is porous it can easily be impregnated like a sponge with a therapeutic homeopathic tincture.
  • the button is then formed with pressure to the desired shape.
  • buttons 30 effectively increases the overall therapeutic effect cf the topical by providing direct physical stimulation of the acupuncture point.
  • the smooth domed top of button 30 is desirable as being less obtrusive on the surface cf the skin.
  • the button 30 is formed and impregnated with medicament, it is magnetically charge so that the desired polarity is imparted to the under surface cf the button which is affixed in place over a pre-selected acupuncture point.
  • One polarity is on the upper surface of the button (the domed surface away from the 1 _ skin) and the other pole is on the lower surface of the button in contact with the skin.
  • Still another form of administering homeopathic medicaments is orally by means of a pill or tablet. Two such oral tablets are shown in Figures 1A and IB.
  • this oral device can aptly be described as a medicinal "lollipop" consisting of a rod portion 40 and a ball or bulbous portion 42.
  • the rod 40 is made up of a metal such as iron capable of holding a magnetic charge.
  • the ball portion 42 has an inert core such as molded plastic, for example.
  • the rod 40 is coated with a plastic or vinyl coating 44 extending to the ball portion 42.
  • the ball portion 42 is coated with a homeopathic composition made of sugar and Ferrous gluconate mixed to a dilution in the range of 3x to 4x. It is then impregnated with an alcohol tincture containing the desired homeopathic medicament.
  • the entire device can be encased in a sanitary wrapping.
  • the entire device in its wrapping if desired is first placed in a suitable electromagnetic field.
  • all of the metallic elements of the device are magnetized with the ball portion being charged with one polarity and the rod portion with the opposite polarity.
  • the therapeutic portion of the device having a unipolar charge can then be placed under the tongue of the patient in order to contact the acupuncture points in the mouth.
  • a pill as shown in Figure IB can be used.
  • the pill 50 has a core 52 formed of a standard homeopathic sugar globule made in conventional manner.
  • Dry Ferrous gluconate powder (USP grade) is triturated with very fine sugar in a 1-9 proportion in a grinding machine to make a homeopathic dilution of 2X.
  • a second dilution (designed as 3X) is made in the same 1-9 proportions using the 2X dilution and additional sugar. Succeeding dry dilutions are made in the same manner to a final dilution of 5X.
  • the 5X dilution of the Ferrous gluconate and sugar is used to build inner layer 54 which surrounds the core 52.
  • Layer 54 is built up by tu bling in a coating pan in accordance with known methods for the manufacture of homeopathic remedies. Layer 54 is then covered with a coating 56 which is impermeable to water and alcohol. Ferrous gluconate is added to coating 56 so that it will have the same magnetic permeability as layer 54 containing ferrous gluconate and sugar. An outer layer 58 is then built up around coating 56 in the same manner as inner layer 54 was formed. The thickness of outer layer 58 should be approximately twice that of inner layer 5? for optimum results and is similarly made of a Ferrous gluconate sugar mixture in 5X dilution. The pills are then thoroughly air dried. The diameter of the finished pill should preferably be approximately one centimeter.
  • the layered pill made a.ccording to this procedure can then be medicated in conventional manner.
  • a measured weight of the finished, dried pills is placed in a suitable container and a predetermined amount of the desired homeopathic medicinal tincture is added.
  • the homeopathic tincture is of a dilution of 3OX which has been manufactured ir. accordance with traditional homeopathic procedure from herbs or other raw materials.
  • the containers with the pills are then rotated in a roller mill for approximately one hour to permit the pills to completely absorb the alcohol tincture.
  • the pills are then transferred from the containers to paper covered trays where they are air drie ⁇ until no trace or odor of the alcohol remains.
  • the pills are then individually packaged (a single pill to each container) in a vial-like tube with a threaded cap or tightly fitting friction lid.
  • the cap is preferably larger in diameter than the vial so that it projects to form a rim around the vial at the top. Pre ⁇ cautions should be taken during processing to avoid contamina ⁇ tion or de-activation of th -pills.
  • the medicated pills can then be administered to the patient.
  • a vial containing the pills is placed into a ⁇ uit- able magnetic filed so that each piil is magnetized just pricr to inge ⁇ tion by the patient.
  • the pill should be inserted directly into the mouth from the vial without handling.
  • the patient can then suck on the pill to gradually dissolve it until the impermeable coating is reached at which point the patient should discard the remainder of the pill.
  • Yet another form of administering the homeopathic medicaments is by auricular measures.
  • One such device consists of an earplug containing dosages of the homeopathic medicament which can be administered through holes in the earplug to the acupuncture points in the ear.
  • the earplug device can be made by any number of means with the understanding that it must be able to uncontrollably release medicament to predetermined auricular acupuncture points. This can best be accomplished by either using rods or small protrusions aligned with the acupuncture points and capable of releasing medicament.
  • the homeopathic medicament is magnetized after it is deposited in the earplug device in accordance with the procedure described above for imparting a magnetic charge to the topical or oral forms of administration.
  • An injectable dosage form of an herb-based homeopathic medicament designated FNG-11, for the treatment of fungus and yeast infections, having a homeopathic potency of SOX was prepared from an original concentrated tincture menstrum containing extracts cf the herbs Tecoma conspicua and
  • Example 2 Melaleuca alternifolia in 99+% alcohol. The original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline. Ferrous gluconate, a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed depending upon the number of acupuncture points being used. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above. Example 2
  • the original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline.
  • Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 X (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field.
  • Injectable dosage portions of 0.2cc volumes were set aside as needed.
  • the formulations injected were controllably magnetized during administration through the acupuncture sites as described above.
  • An injectable dosage form of an herb-based homeopathic medicament designated VR-27, for the treatment of broad spectrum viral infections, having a homeopathic potency of SOX was prepared from an original concentrated tincture menstruum containing an extract of the herb Centella asiatica minor in 99+% alcohol. The original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline. Ferrous gluconate, a magnetically permeable substance in a homeopathic potency cf 4 x (10-4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field. Injectable dosage portions cf 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above. Example 4
  • the original concentrated tincture was then diluted to 30X potency (10 ⁇ " times the original concentration) with sterile isotonic saline.
  • Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed.
  • An injectable dosage form of an herb-based homeopathic medicament for the treatment of hypothyroidism, was prepared from an original concentrated tincture menstruum containing an extract of the herb Organ protomcrpho im in 99+% alcohol. The original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline. Ferrous gluconate, a magnetically permeable substance in a homeopathic potency of 4 x (10 -4-) , was added to the dilute homeopathic solution in order for it to hol a magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above.
  • An injectable dosage form of an herb-based homeopathic medicament for the treatment of premenstrual syndrome, menopause, and reproductive hormonal imbalance, was prepared from an original concentrated tincture menstruum containing an extract of the herb Angelica sinensis in 99+% alcohol.
  • the original concentrated tincture was then diluted to 30X potency (10 times the original concentration) with sterile isotonic saline.
  • Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 x 10 ) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field.
  • Injectable dosage portions of 0.2cc volumes were set aside as needed.
  • Example 7 An injectable dosage form of a homeopathic medicament, designated HYT-12, for the treatment of hydro- thyroidism, was prepared from an original concentrated tincture menstruum containing a solution of aqueous iodine in
  • the original concentrated tincture was diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline.
  • Ferrous gluconate a magnetically permeable substance in. a homeopathic potency of 4 x f!0 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field.
  • Injectable dosage portions of 0.2cc volumes were set aside as needed.
  • the formulations injected were controllably magnetized during administration through the acupuncture sites as described above.
  • Example 8 An injectable dosage form of an herb-based homeopathic medicament for the treatment of hypertension, designated RLX-22, was prepared from an original tincture menstruu containing extracts of the herbs Rock Pose, Clematis, Impatien ⁇ , Cherry Plum, and Star of Bethlehem in
  • An injectable dosage form of an herb-based homeopathic medicament, designated IMM-2, for restoring and strengthening the body's natural immune system, having a homeopathic potency of 30X was prepared from an original concentrated tincture menstruum containing extracts of the herbs Astragalus membranaceous, Nux vomica, Panix ginseng, Germanium and extract of Thymus gland in 99+% alcohol. The original concentrated tincture was then diluted to 3OX potency (10 -30 times the original concentration) with sterile isotonic saline.
  • Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field.
  • Injectable dosage portions of 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above.
  • An injectable cc ⁇ are form of a homeopathic medicament for the treatment of hypoglycemia designated HYG-6, was prepared from an original concentrated tincture menstruum containing sulfur and glycerin in 99+% alcohol. The original concentrated tincture was then diluted to 30X potency (10 -30 times the ori ⁇ inal concentration) with sterile isotonic saline. Ferrous gluconate, a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge w en passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed.
  • Example 11 An injectable dosage form of an herb-based homeopathic medicament, designated INF-16, for the treatment of bacterial infections, particularly staff and strep, was prepared from an original concentrated tincture menstruum containing extracts of the herbs Senecia scandens, Scutellaria baicalensis, Magnolia officinalis, Lonicera japonica, and
  • Andrographis paniculata in 99+% alcohol was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline.
  • Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field.
  • Injectable dosage portions cf 0.2cc volumes were set aside as needed.
  • An injectable dosage form of an herb-based homeopathic medicament, designated FLU-17, for the treatment of viral infections due to colds and influenza, particularly rhino-virus, was prepared from an original concentrated tincture menstruum containing extracts of the herbs Lonicera confusa. Chrysanthemum indicum, Vitex negundo, Eucdia epta, Ilex asprella, Menthol, and Baphicacan hu ⁇ cu ⁇ ia in 99+% alcohci. The original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline.
  • Ferrous gluconate a magnetically — A permeable substance in a homeopathic potency of 4 x (10 * ) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above.
  • Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized at the time of administration through the acupuncture sites as described above.
  • Example 14
  • An injectable dosage form of an herb-based homeopathic medicament for the treatment of chronic muscular and joint pain, was prepared from an original ccncentrated tincture menstruuiri containing an extract of the herb Rhus toxicodendron in 99+% alcohol. The original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline. Ferrous gluconate, a magnetically permeable substance in a homeopathic potency cf 4 (10 -4) , was added to the dilute homeopathic solution in order for it to hold ⁇ magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above. Example 15
  • SMK-30 An injectable dosage form of ⁇ homeopathic medicament, designated SMK-30, for the treatment of nicotine addiction and the craving to smoke cigarettes, other nicotine containing tobacco products, and the like, having a homeopathic potency cf 3OX was prepared from an original
  • An oral dosage form of the herb-based homeopathic medicament FNG-11, prepared as set forth in Example 1 above, 25 having a homeopathic potency of 3OX was prepared in accordance with the procedure described above in connection with the pill illustrated in Figure IB.
  • Example 20 An oral dosage form of the herb-based homeopathic medicament SPN-7 , as in Example 4, having a homeopathic potency cf SOX, was prepared according to the method of Example 16.
  • Example 20 An oral dosage form of the herb-based homeopathic medicament SPN-7 , as in Example 4, having a homeopathic potency cf SOX, was prepared according to the method of Example 16.
  • Example 21 An oral dosage form of the homeopathic medicament TYR-10, as in Example 5, having a homeopathic potency of 30X, was prepared according to the method of Example 16.
  • Example 21 An oral dosage form of the homeopathic medicament TYR-10, as in Example 5, having a homeopathic potency of 30X, was prepared according to the method of Example 16.
  • Example 22 An oral dosage form of the herb-based homeopathic medicament HRM-4, as in Example 6, having a homeopathic pctency of 30X, was prepared according to the method of Example 16.
  • Example 22 An oral dosage form of the herb-based homeopathic medicament HRM-4, as in Example 6, having a homeopathic pctency of 30X, was prepared according to the method of Example 16.
  • Example 23 An oral dosage form of the herb-based homeopathic medicament RLX-22, as in Example 8, having a homeopathic pctency cf 30X, was prepared according to the method of Example 16.
  • Example 24 An oral dosage form cf the herb-based homeopathic medicament IMM-2, as in Example 9, having a homeopathic potency of 30X, was prepared according to the method of Example 16.
  • Example 25 An oral dosage form cf the herb-based homeopathic medicament HYG-6, as in Example 10, having a homeopathic potency of 3OX, was prepared according to the method cf Example 16.
  • Example 26 An oral dosage form cf the herb-based homeopathic medicament I1F-16, as in Example 11, havir. ⁇ ⁇ homeopathic potency of 30X, was prepared according to the method of Example 16.
  • Example 27 An oral dosage form cf the herb-based homeopathic medicament I1F-16, as in Example 11, havir. ⁇ ⁇ homeopathic potency of 30X, was prepared according to the method of Example 16.
  • Example 28 An oral dosage form of the herb-based homeopathic medicament GLG-17, as in Example 12, having a homeopathic potency of 30X, was prepared according to the method of Example 16.
  • Example 28
  • Example 29 An oral dosage form of the herb-based homeopathic medicament ALL-5, as in Example 13, having a homeopathic potency of SOX, was prepared according to the method of Example 16.
  • Example 29 An oral dosage form of the herb-based homeopathic medicament ALL-5, as in Example 13, having a homeopathic potency of SOX, was prepared according to the method of Example 16.
  • Example 30 An oral dosage form of the herb-based homeopathic medicament OPN-26, as in Example 14, having a homeopathic potency of 30X, was prepared according to the method of Example 16.
  • Example 30
  • Example 16 where the original concentrated tincture menstruum contained extracts of the herb Coryandru ⁇ ⁇ ativa.
  • Example 31 A combined treatment regimen utilizing both the injectable and oral dosage forms of the FNG-11 homeopathic medicament (prepared according to Examples 1 and 16, respectively) , was used in the treatment of a 44 year old female patient. Prior to treatment the patient exhibited symptoms including mood swings, premenstrual syndrome (P. .S.), and fatigue, and was diagnosed as a result of visible yeast in a live cell analysis as suffering from candidiasis.
  • the injectable form dosage of FNG-11 was administered two times per week during the first week and once per-week thereafter bilaterally to the two SP-6 acupuncture points. Duration of treatment by the injectable mode was for a total period of four weeks.
  • Oral dosage forms were admini ⁇ tered at an initial dosage rate of 3 tablets taken 5 times per day during the first week of treatment, reduced to 3 times per day during the second week of treatment and finally to 2 times per day for the balance of the duration of the treatment.
  • the total duration of treatment under the oral form was for a period of 4 weeks.
  • the patient's blood level yeast decreased by 60%.
  • the patient's P.M.S. and other symptoms were controlled.
  • Example 32 A combined treatment regimen utilizing both the injectable and oral dosage forms of the VR-27 homeopathic medicament (prepared according to Examples 3 and 18, respectively) , was used in the treatment of a 41 year old male exhibiting symptoms including a histcry cf prostatiti ⁇ and gonorrhea with active leiscn ⁇ approximately 60-70% of the time. The patient was diagnosed as being infected with herpes simplex 2.
  • the injectable form dosage of the VR-27 was administered two times per week during the first week and once per week thereafter bilaterally to the two Tk-5 acupuncture points and the oral form dosage was administered initially at a rate of 3 tablets taken 5 times per day during the first week of treatment, reduced to 3 times per day during the second week of treatment and finally to 2 times per day for the balance of the duration of the treatment. Both the injectable and oral form dosages were administered for a total treatment period of 6 weeks. After 3 weeks of treatment, the patient 8 s condition improved to the extent that there were no active lesions and no further outbreaks of genital herpes.
  • Example 33 A combined treatment regimen of oral and injectable forms of VR-27 was utilized in the treatment of a 33 year old female of slender build and good muscle structure.
  • the patient exhibited classic symptoms of Chronic Epstein-Barr Virus including chronic fatigue, unrefreshed sleep, dark circles under the eyes, headaches, burning eyes, hypersensitivity to bright lights and smoke, non-specific muscle aches in shifting locales, lack of coordination, lack of balance, and persistent bouts of depressions that sometimes reached profound levels. She was uncertain of exact dates but felt that she had had most of these symptoms for several years.
  • VGA E-B Virus antibody virus titer
  • the patient was treated on a weekly basis with the homeopathic medicament by taking 3 oral tables t.i.d.
  • the injectable form of VR-27 was injected through the TW-5 acu- puncture point.
  • Treatment continued for a period of approxi ⁇ mately 2 months.
  • the follow-up blood work shewed that the same anti-body titer had fallen to a level of 1:320; well below the critical point and within the range considered normal.
  • the clinical signs and symptoms confirmed the lab work and the patient reported virtual freedom from the previous physical and emotional problems. She continued to be free of symptoms 18 months later.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un procédé de traitement d'états pathogènes du corps humain consiste à préparer un mélange d'au moins une herbe, extrait d'herbe ou autre composé doté de propriétés thérapeutiques, à ajouter une substance magnétiquement perméable au mélange, à magnétiser le mélange ainsi obtenu de façon à lui conférer une charge magnétique sensiblement unipolaire et à administrer le mélange magnétisé à travers un ou plusieurs points spécifiques d'acupuncture associés à la production d'une réponse voulue affectant l'état particulier soumis au traitement. L'invention concerne également le traitement de maladies diverses par administration orale, auriculaire ou topique ou par injection de médicaments homéopathiques.
PCT/US1989/001400 1988-04-01 1989-04-03 Preparations pharmaceutiques homeopathiques magnetiquement influencees, leurs procedes de preparation et d'administration WO1989009049A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN258/CAL/89A IN169075B (fr) 1988-04-01 1989-04-05
IN1043/CAL/90A IN171749B (fr) 1988-04-01 1992-12-19

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17673188A 1988-04-01 1988-04-01
US176,731 1988-04-01

Publications (1)

Publication Number Publication Date
WO1989009049A1 true WO1989009049A1 (fr) 1989-10-05

Family

ID=22645606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/001400 WO1989009049A1 (fr) 1988-04-01 1989-04-03 Preparations pharmaceutiques homeopathiques magnetiquement influencees, leurs procedes de preparation et d'administration

Country Status (7)

Country Link
EP (1) EP0409893A4 (fr)
JP (1) JPH03503648A (fr)
AU (1) AU632481B2 (fr)
CA (1) CA1334936C (fr)
IN (1) IN169075B (fr)
NZ (1) NZ228593A (fr)
WO (1) WO1989009049A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0469661A1 (fr) * 1990-08-01 1992-02-05 Enza Ciccolo Procédé d'identification de fréquence et d'activité bioénergique des eaux et leur utilisation
FR2675385A1 (fr) * 1991-04-18 1992-10-23 Boulay Maurice Produit calmant et revitalisant contenant de la poudre d'aimant.
WO1997001355A1 (fr) * 1995-06-26 1997-01-16 Antonio Sacchetti Excitation de substances naturelles induite par voie magnetique ou electromagnetique
WO2002066041A1 (fr) * 2001-02-23 2002-08-29 Herbal Detox Therapy Aps Composition naturelle
US6552035B2 (en) * 2001-09-13 2003-04-22 Hwa-Mok Park Composition for inducing smoking cessation comprising alkaloids from Radix ipecauanhae
US6844014B1 (en) 2002-07-22 2005-01-18 Stephen Rafkin Herbal healing lotion for veterinary use
EP3166620A1 (fr) * 2014-07-11 2017-05-17 Marianna Gross Agent homéopathique pour le sevrage tabagique

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003712A1 (fr) * 1991-08-20 1993-03-04 Daniel Mcnair Dispositif permettant d'administrer des compositions homeopathiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501726A (en) * 1981-11-12 1985-02-26 Schroeder Ulf Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
JPS63159313A (ja) * 1986-12-24 1988-07-02 Olympus Optical Co Ltd 治療用薬剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2671451A (en) * 1952-06-16 1954-03-09 Stephen J Bolger Remedial pill
DE1467974A1 (de) * 1964-06-08 1969-01-23 Tsukamoto Kenkichi Verfahren zur Verbesserung der Wirksamkeit von Eisenpraeparaten und Vorrichtung zur Durchfuehrung des Verfahrens
DE1492136A1 (de) * 1965-01-30 1969-09-18 Seuss Dr Med Willy Einrichtung zur therapeutischen Beeinflussung des menschlichen Koerpers durch statische Elektrizitaet
DE1692771A1 (de) * 1968-02-24 1972-01-05 Willy Dr Med Seuss Verfahren zur Zubereitung innerlich oder aeusserlich anwendbarer physiologisch wirksamer Stoffe und danach hergestellte Mittel
BE759692A (fr) * 1969-12-23 1971-05-17 Soliman Henri Medicament mineralo-vegetal
FR2258839A1 (en) * 1974-01-28 1975-08-22 Sitbon Georges Colloidal therapeutic iron solutions - treatment for cancer, leukaemia, arterial and cardiac disorders, neurological disorders, anti-radiation agents, etc.
SE431214B (sv) * 1977-06-02 1984-01-23 Klaus H Mosbach Sett att framstella magnetiska polymerpartiklar som berare av en foretredesvis biologiskt aktiv substans
US4357259A (en) * 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
JPS576041A (en) * 1980-02-25 1982-01-12 Kimikiyo Harada Folding formation type metal stud
FR2477022A1 (fr) * 1980-03-03 1981-09-04 Flux Yang Ste Civile Dispositif pour l'application localisee d'un champ magnetique sur un objet, notamment un etre vivant
JPS5945378A (ja) * 1982-09-09 1984-03-14 Toyobo Co Ltd 粘着材料
JPS6032716A (ja) * 1983-07-29 1985-02-19 Yasuo Sawada 特殊脂肪酸と磁化鉄粉含有の殺菌薬と病体の恢復力を速める薬の製造方法
JPS61115015A (ja) * 1984-11-08 1986-06-02 Shimazaki Shiyubiyou Kk 帯磁化粧品
EP0208362A1 (fr) * 1985-06-28 1987-01-14 The Procter & Gamble Company Suppléments alimentaires contenant du calcium à revêtement soluble dans l'intestin et du fer
JPS62175419A (ja) * 1986-01-25 1987-08-01 Tomoji Tanaka 人工温泉浴剤
DE3634121A1 (de) * 1986-05-09 1987-11-12 Otto Kausch Verfahren und einrichtung zur verbesserung der wirkungen fluessiger oder pastoeser praeparate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501726A (en) * 1981-11-12 1985-02-26 Schroeder Ulf Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
JPS63159313A (ja) * 1986-12-24 1988-07-02 Olympus Optical Co Ltd 治療用薬剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0409893A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0469661A1 (fr) * 1990-08-01 1992-02-05 Enza Ciccolo Procédé d'identification de fréquence et d'activité bioénergique des eaux et leur utilisation
FR2675385A1 (fr) * 1991-04-18 1992-10-23 Boulay Maurice Produit calmant et revitalisant contenant de la poudre d'aimant.
WO1997001355A1 (fr) * 1995-06-26 1997-01-16 Antonio Sacchetti Excitation de substances naturelles induite par voie magnetique ou electromagnetique
WO2002066041A1 (fr) * 2001-02-23 2002-08-29 Herbal Detox Therapy Aps Composition naturelle
US6552035B2 (en) * 2001-09-13 2003-04-22 Hwa-Mok Park Composition for inducing smoking cessation comprising alkaloids from Radix ipecauanhae
US6844014B1 (en) 2002-07-22 2005-01-18 Stephen Rafkin Herbal healing lotion for veterinary use
EP3166620A1 (fr) * 2014-07-11 2017-05-17 Marianna Gross Agent homéopathique pour le sevrage tabagique
CN106714815A (zh) * 2014-07-11 2017-05-24 M·格罗斯 促使吸烟者戒烟的顺势疗法药剂

Also Published As

Publication number Publication date
CA1334936C (fr) 1995-03-28
EP0409893A4 (en) 1991-03-13
AU632481B2 (en) 1993-01-07
NZ228593A (en) 1992-07-28
IN169075B (fr) 1991-08-31
EP0409893A1 (fr) 1991-01-30
AU3426089A (en) 1989-10-16
JPH03503648A (ja) 1991-08-15

Similar Documents

Publication Publication Date Title
US5162037A (en) Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
TWI352597B (en) Composition having effect of moxibustion and press
AU723812B2 (en) Medicinal preparation and a method of medicinal action on human organism
US4352796A (en) Pharmaceutically active plant extract and composition thereof
WO2009051628A2 (fr) Dispositif de traitement transdermique et procédé
CN101417013A (zh) 一种用于风湿骨痛的中药巴布剂及其制备方法
EP1162988A1 (fr) Systeme d'apport par cachet
AU632481B2 (en) Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
CN106038479B (zh) 一种蛇床子微囊温敏凝胶及其制备方法与质量检测方法
US5603935A (en) Composition for the treatment of snoring and methods of use thereof
CN103495042A (zh) 一种用于治偏头痛的中药组合物
CN102302559B (zh) 一种呼吸系统疾病药及其应用
CN104623376A (zh) 用于治疗三叉神经痛的药物
RU2346696C2 (ru) Способ стимуляции иммунной системы человека активированным минералом, содержащим платиноиды, способ активации минерала и состав, обладающий свойствами стимуляции иммунной системы
CN102552440B (zh) 一种平喘消炎药物及其制备方法和用途
CN101361868B (zh) 一种治疗风湿的中药组合物
CN102614375B (zh) 一种补肾壮阳、治疗阳痿的中药组合物及其制备方法
CN101181602B (zh) 一种中药制剂、其制备方法及在制备抗病毒、抗菌药物中的应用
Biddle Materia medica
CN1080563C (zh) 向日葵秆芯作为制备治疗癌症的药剂的用途
CN1092976C (zh) 苦荬菜在制备治疗结核病药物方面的用途
AU2002254806B2 (en) Herbal composition for the treatment of drug addiction and insomnia
CN1116106A (zh) 治疗女性外生殖器疾患的药物制剂洁阴净
CN103599185A (zh) 一种用于治疗头痛的中药组合物
CN113304242A (zh) 一种补肾壮阳的药酒

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR DK FI HU JP LK NO SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1989904967

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989904967

Country of ref document: EP